Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
Conclusion:
Concurrent chemoradiotherapy with raltitrexed and nedaplatin agents frequently caused myelosuppression but was highly active and suggested to be a promising treatment option for locally advanced ESCC.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Clinical Trials | Esophagus Cancer | Internal Medicine | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology